Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

(2022) Heba N. Altarawneh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

(2022) Daniel R Feikin et al.   LANCET

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England

(2022) Freja C M Kirsebom et al.   LANCET INFECTIOUS DISEASES

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

(2022) Hiam Chemaitelly et al.   Nature Communications

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022

(2022) Kristie E.N. Clarke et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Use of At-Home COVID-19 Tests — United States, August 23, 2021–March 12, 2022

(2022) Benjamin Rader et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5

(2022) Nicole P. Hachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

(2021) Mark G. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE